glp-1 trial results today Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating The latest results from a
Description
Physiol Rev 95:513-548
Commun Med
Peptide YY and other satiety peptides demonstrate clear physiological roles, with early failures attributable to rapid exposure and intolerance rather than to a lack of efficacy, again favoring re-evaluation
But there are weight and health requirements, and those who already get GLP-1s covered for diseases like diabetes and sleep apnea won't qualify
10.3389/fendo.2019.00155 [DOI] [PMC free article] [PubMed] [Google Scholar] Krashes, M
